![What oncologists say about the new approval of Lazertinib and amivantamab for advanced NSCLC](https://oncodaily.com/pub/uploads/2024/06/print-202768569.png)
What oncologists say about the new approval of Lazertinib and amivantamab for advanced NSCLC
On August 19, 2024, the FDA approved a new combination therapy for advanced non-small cell lung cancer (NSCLC). Lazertinib (Lazcluze) and amivantamab-vmjw (Rybrevant), both from Janssen Biotech, Inc., can now be used together as a first-line treatment for patients with locally advanced or metastatic NSCLC who have specific genetic mutations, like EGFR exon 19 deletions or exon 21 L858R substitutions, as detected by an FDA-approved test.
Ishwaria Subbiah shared on LinkedIn:
“Started the day with an FDA oncology approval — lazertinib + amivantamab-vmjw for non-small lung cancer!
- Perfect time to get ready with the supportive care symptom management plan for our patients!
- The most common adverse reactions (≥20%) were rash, nail toxicity, musculoskeletal pain, edema, stomatitis, paresthesia, fatigue, diarrhea, constipation, dry skin, decreased appetite, pruritus, and nausea. “
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors.
He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.